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Tissue homeostasis in metazoans is regulated by
transitions of cells between quiescence and prolifer-
ation. The hallmark of proliferating populations is
progression through the cell cycle, which is driven
by cyclin-dependent kinase (CDK) activity. Here, we
introduce a live-cell sensor for CDK2 activity and un-
expectedly found that proliferating cells bifurcate
into two populations as they exit mitosis. Many cells
immediately commit to the next cell cycle by building
up CDK2 activity from an intermediate level, while
other cells lack CDK2 activity and enter a transient
state of quiescence. This bifurcation is directly
controlled by the CDK inhibitor p21 and is regulated
by mitogens during a restriction window at the
end of the previous cell cycle. Thus, cells decide at
the end of mitosis to either start the next cell cycle
by immediately building up CDK2 activity or to enter
a transient G0-like state by suppressing CDK2
activity.INTRODUCTION
Metazoans tightly control the number of cells in each tissue dur-
ing development and throughout adult life. Imbalances between
the creation and removal of cells lead to excessive tissue growth
or failure of tissue function. Much of this feat of balanced tissue
homeostasis is achieved by switching cells between two
different states: proliferative and quiescent. The transitions
between proliferation and quiescence are often reversible—cells
must be able to switch from a proliferative to a quiescent state
(also termed G0) and later re-engage the proliferation machinery
from the quiescent state. A better understanding of these transi-
tions is not only important to understand normal development
and adult physiology but also to identify better therapeutic ap-
proaches for diseases that involve excessive proliferation, such
as cancer, or net cell loss, such as aging and neurodegeneration.
Although reduced levels of mitogens, contact inhibition, and
various stress conditions are known to promote quiescence,and many molecular regulators of proliferation have been identi-
fied, the detailed mechanisms that control the transitions
between these two states are still poorly understood. In one
prominent model, cells are thought to commit to the cell cycle
at a ‘‘restriction point’’ in late G1 (Pardee, 1974). This model
was based on experiments in which mitogen-starved cells
were restimulated for varying amounts of time to identify a point
when the presence of mitogens is no longer necessary to com-
plete the cell cycle. Cells that have crossed the restriction point
prior to mitogen removal are committed to completing the cell
cycle, whereas cells that have not crossed the restriction point
at the time of mitogen withdrawal remain in G0 or G1.
Much is known about the molecular events associated with
emergence from a mitogen-starved state. In mitogen-starved
cells, CDK activity is off, and the CDK substrate retinoblastoma
protein (Rb) is hypophosphorylated, resulting in an inhibition of
E2F transcriptional activators. Re-exposure of cells to mitogens
triggers CDK4/6-dependent phosphorylation of Rb, which initi-
ates the reactivation of E2F. Active E2F induces expression of
cyclin E and other proteins that promote CDK2 activity, leading
to further phosphorylation of Rb (Massague´, 2004; Trimarchi
and Lees, 2002). This reinforced expression of cell-cycle regu-
lators is thought to engage in G1 a few hours before DNA
replication, causing an upregulation of CDK2 activity, full phos-
phorylation of Rb, and passage through the restriction point
(Dou et al., 1993; Weinberg, 1995; Yao et al., 2008; Zetterberg
et al., 1995). Ubiquitination and degradation of the CDK inhibitor,
p21, is also thought to promote the G1/S transition (Abbas and
Dutta, 2009). Despite a significant amount of knowledge about
the biochemical processes associated with emergence from
quiescence, much less is known about cell-cycle commitment
in proliferating cells.
Because cycling cell populations are asynchronous, biochem-
ical analysis of commitment mechanisms cannot readily be per-
formed. Chemical and other synchronization methods can be
used to obtain more homogeneous populations, but these pro-
cedures can trigger stress responses and may alter the natural
behavior of cells. In addition, bulk analysis may mask the exis-
tence of distinct sub-states in a population. Even if single-cell
methods are used, the lack of accepted molecular markers
that distinguish precommitment from postcommitment cells or
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Figure 1. Characterization of a Live-Cell Sensor for CDK2 Activity
(A) Cell-cycle diagram showing uncertainty about when entry into G0 occurs and where the restriction point (R) is positioned.
(B) Schematic of sensor. NLS, nuclear localization signal; NES, nuclear export signal; S, CDK consensus phosphorylation site on serine.
(C) Schematic of CDK2 phosphorylation-mediated translocation of DHB-Ven.
(D) Method used to obtain the cytoplasmic to nuclear ratio of DHB-Ven. Cell nuclei were identified using fluorescent H2B images to obtain a mask. The nuclear
component of DHB-Ven was determined using this mask, whereas the cytoplasmic component of DHB-Ven consisted of a ring around the nuclear mask. See
Extended Experimental Procedures.
(legend continued on next page)
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there has been a long-standing debate over where between
mitosis and S phase G0 ought to be placed (Coller, 2007)
(Figure 1A).
Here, we introduce a fluorescent sensor to monitor CDK2
activity in single cycling cells. Using time-lapse microscopy
and customized cell tracking, we monitored CDK2 activity over
several cell cycles in an immortalized but nontransformed
human mammary epithelial cell line, MCF10A. We confirmed
our results in primary human foreskin fibroblasts and in a previ-
ously used model for cell-cycle progression, murine Swiss 3T3
fibroblasts. By studying unperturbed, asynchronous cultures,
we discovered a bifurcation point at mitotic exit where cells
choose between two different fates. Many cells exit mitosis
with an intermediate level of CDK2 activity, from which they
continue to build up CDK2 activity and complete the next cell
cycle. The remaining cells enter a transient state of quiescence
characterized by low CDK2 activity. We show that cells
integrate mitogenic signals during a ‘‘restriction window’’ at the
end of the previous cell cycle to decide which of the two paths
to take upon completion of mitosis. Finally, using immunofluo-
rescence, genetics, and chemical biology approaches, we
show that the bifurcation in cell fate is directly controlled by
the CDK inhibitor, p21.
RESULTS
Characterization of a Live-Cell Sensor for CDK2 Activity
We adapted a previously described sensor for the G1/S transi-
tion (Hahn et al., 2009) to quantitatively measure changes in
CDK activity. The sensor includes amino acids 994–1087 of
human DNA helicase B fused to the yellow fluorescent protein
mVenus (DHB-Ven; Figure 1B), and contains four CDK
consensus phosphorylation sites, a nuclear localization signal,
and a nuclear export signal (Gu et al., 2004). We established
an MCF10A line stably expressing this construct and found
that DHB-Ven localizes to the nucleus in newly born cells. The
sensor then translocates progressively out of the nucleus as
the cell cycle proceeds and exhibits cytosolic localization at
the end of G2 (Figure 1C). We used the cytoplasmic to nuclear
ratio (Cyt/Nuc) of DHB-Ven fluorescence intensity as a potential
readout for CDK activity. Tomeasure this ratio, we compared the
nuclear DHB-Ven signal to the intensity of a region outside, but
adjacent to, each nucleus (Figure 1D).(E) Purified GST-DHB (aa994–1087) at six different concentrations was used in
complexes. Conditions were selected to be in a range known to work with the esta
a high level of basal autophosphorylation. See Extended Experimental Procedur
(F) Images of DHB-Ven in a single cell before and after treatment with 10 mM CD
(G) DHB-Ven traces in individual MCF10A cells before (imaged every 12 min) and
line). The half-life was derived from an exponential fit to the average of individua
(H) In vivo response of DHB-Ven to titration of eight different kinase inhibitors. Ce
imaged to obtain the median of single-cell Cyt/Nuc DHB-Ven signals in each we
(I) Comparison of DHB-Ven and two other CDK2 substrates, Cdc6 and Rb, to a
96-well plate format, fixed, stained with antibodies (anti-phosphorylated Rb at ser
the cytoplasm in response to CDK2 phosphorylation) and imaged to obtain the m
Cdc6 signals or median of single-cell pRb signals in each well. Error bars repres
(J and K) Density scatter plot of pRb807/811 versus DNA content (J) or Cyt/Nuc D
Single-parameter histograms are shown above and to the right. Scale bars throu
All data are from MCF10A cells. See also Figure S1.An in vitro kinase activity screen using a panel of CDK/cyclin
pairs and amino acids 994–1087 of DHB revealed that DHB is
phosphorylated strongly by CDK2/cyclin A, more weakly by
CDK2/cyclin E, and is not phosphorylated by CDK1/cyclin B,
CDK4/cyclin D, or CDK6/cyclin D (Figure 1E). Using small mole-
cule inhibitors in vivo, we showed that the cytoplasmic localiza-
tion of DHB-Ven was reversed by addition of a CDK1/2 inhibitor
(Figures 1F and 1G) but was not altered by treating cells with
selective inhibitors targeting CDK4/6, EGFR, MEK, p38, Akt, or
PI3K across a wide range of doses (Figures 1H and S1 available
online). The localization of DHB-Ven was also unaffected by
addition of a CDK1-selective inhibitor (Figure 1H), arguing that
the sensor responds primarily to CDK2 activity, at least in cells
where CDK2 is present. Treatment of cells with the CDK1/2 in-
hibitor caused retro-translocation of DHB-Ven from the cyto-
plasm to the nucleus with a half-life of 7 min (Figures 1F and
1G), showing that DHB-Ven responds rapidly to changes in
CDK2 activity. Furthermore, the rate of translocation of DHB-
Ven did not significantly depend on when during interphase we
added the CDK1/2 inhibitor (Figure S1), arguing that the phos-
phatase activity acting on the sensor is relatively constant during
interphase.
We then compared the sensitivity of the response of DHB-Ven
to that of two established CDK2 substrates (Cdc6 and Rb) using
titration of the CDK1/2 inhibitor (Figure 1I). We found that the
three substrates had very different EC50 values, with DHB-Ven
being 3.5-fold and 23-fold more sensitive to the inhibitor than
Cdc6 and Rb, respectively. Thus, Rb is a highly sensitive CDK2
substrate, meaning it takes very little CDK2 activity to phosphor-
ylate Rb, whereas DHB-Ven required a higher level of CDK2
activity to become phosphorylated. When we examined the
phosphorylation status of Rb and the localization of DHB-Ven
as a function of DNA content in single cells, we found that cells
can have hyperphosphorylated Rb already in G1 when they still
have a 2N DNA content (Figure 1J). In contrast, DHB-Ven was
only partially phosphorylated when cells have a 2N DNA content
(Figure 1K). The phosphorylation and consequent cytoplasmic
translocation of DHB-Ven then gradually increased as cells pro-
gressed through the cell cycle and the DNA content increased
from 2N to 4N. This implies that CDK2 activity progressively in-
creases throughout interphase, and that the DHB-Ven sensor
has a dynamic range well-suited to monitor changes in CDK2
activity throughout the cell cycle.an in vitro kinase activity assay as a substrate for five different cyclin-CDK
blished artificial positive control, RBER-CHKtide. Note that CDK1/cyclin B has
es.
K1/2 inhibitor.
after (imaged every 2 min) treatment with 10 mM CDK1/2 inhibitor (red dashed
l traces (red curve).
lls were treated with the inhibitors for 30 min in 96-well plate format, fixed, and
ll.
titration of CDK1/2 inhibitor. Cells were treated with the inhibitor for 30 min in
ine 807/811 [pRb807/811] or anti-Cdc6; Cdc6 translocates from the nucleus to
edian of single-cell Cyt/Nuc DHB-Ven signals, median of single-cell Cyt/Nuc
ent the standard deviation of duplicate wells.
HB-Ven versus DNA content (K) in single cells obtained by fixed-cell imaging.
ghout this manuscript are 10 mm.
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Variable Delay in the Activation of CDK2 in Cells
Emerging from Mitogen Starvation
To further validate our sensor, we compared single-cell time-
lapse measurements of DHB-Ven to earlier bulk experiments in
which cells were synchronized by mitogen starvation, restimu-
lated with mitogens, and then lysed for biochemical analysis
after varying amounts of time. These earlier studies described
an increase in CDK2 activity in late G1 followed by entry into
S phase (Dulic et al., 1992; Koff et al., 1992; Ohtsubo et al.,
1995) (Figure 2A). Because adherent cells migrate over time,
we developed a custom script to track cells and monitor CDK2
activity in thousands of individual cells through several cell
cycles (Figure 2B; Extended Experimental Procedures) and
made use of a 96-well plate format to test different conditions
in the same experiment. In addition to the CDK2 sensor, we
monitored the time of entry into S phase in single cells using
SCFSkp2-mediated degradation of a fluorescently tagged frag-
ment of Cdt1 (Sakaue-Sawano et al., 2008) (Figures 2C and S2).
When we tracked CDK2 activity in individual cells emerging
from mitogen starvation, we observed a period of roughly 8 hr
of low CDK2 activity, followed by a broad time window during
which individual cells triggered a buildup in CDK2 activity (Fig-
ure 2D; Movie S1). These dynamics of CDK2 activity are consis-
tent with results from earlier biochemical experiments. Once the
increase in CDK2 activity began in a cell, CDK2 activity
continued to increase monotonically. When DHB-Ven reached
a Cyt/Nuc ratio of approximately one, cells consistently entered
S phase. CDK2 activity then continued to increase for another
16 hr during S and G2 until the nuclear envelope broke down
and the Cyt/Nuc ratio of DHB-Ven became ill-defined until
nuclear envelope reformation. Our results also revealed a large
cell-to-cell variation in the delay between mitogen restimulation
and CDK2 activation, to the extent that some cells in the popu-
lation failed to build upCDK2 activity at all during the 40 hr obser-
vation period. Finally, using siRNA targeting cyclin A, we showed
that the initial rise in CDK2 activity (up to a Cyt/Nuc DHB-Ven ra-
tio of one) did not require cyclin A, but the subsequent rise in
CDK2 activity did, consistent with a requirement for cyclin A in
S phase (Figure 2E).
A Bifurcation in CDK2 Activity at Mitotic Exit in
Asynchronously Cycling Cells
Although the emergence of cells from serum starvation has been
extensively studied, it has not previously been possible to study
unperturbed cells at a molecular level due to the asynchronous
nature of proliferating populations. When we examined CDK2
activity traces from individual cycling MCF10A cells, we noticed
two distinct behaviors (Figure 3A and Movie S2), which became
even more apparent when we aligned multiple traces of CDK2
activity to the time of anaphase (Figure 3B). In the majority of
MCF10A cells (75%), CDK2 activity began to increase immedi-
ately after mitosis from an intermediate level (designated
CDK2inc; blue, Figure 3B); these cells had short intermitotic times
of 16–20 hr. The remaining cells (25%) entered a reversible state
of low CDK2 activity (designated CDK2low; red, Figure 3B); these
cells had heterogeneous intermitotic times ranging from 20 hr to
>50 hr, reminiscent of a G0-like state. These CDK2low cells could
later re-enter the proliferative state by increasing CDK2 activity,372 Cell 155, 369–383, October 10, 2013 ª2013 Elsevier Inc.indicating that these cells remained cell-cycle competent.
Indeed, the CDK2inc and CDK2low cells are not fixed subpopula-
tions, but rather could interconvert at mitotic exit (Figures 3A and
S3). The two behaviors can be reliably distinguished as early as
2 hr after anaphase, approximately 1 hr after nuclear envelope
reformation. The roughly unimodal distribution of CDK2 activity
at 2 hr after anaphase quickly evolved into a clearly bimodal dis-
tribution by 4 hr after anaphase (Figure S3). We therefore set a
threshold in the Cyt/Nuc ratio of DHB-Ven at 2 hr after anaphase
and found that the level of CDK2 activity above or below this
threshold was highly predictive of whether a cell would enter
the CDK2inc or CDK2low state, respectively (Figure S3).
To verify that CDK2inc and CDK2low are really two distinct cell
states, we treated asynchronously cycling cellswith aMEK inhib-
itor to test whether MEK inhibition would prevent CDK2low cells
from reactivating CDK2 activity. When we examined only those
cells that receivedMEK inhibitor 1–3 hr after anaphase, we found
that we were able to block the reactivation of CDK2low cells. In
contrast, MEK inhibition had no effect on the already increasing
CDK2inc trajectories. Thus, a clear decision is made at the end
of mitosis that causes a bifurcation in cell fate in which CDK2inc
cells no longer require MEK activity to complete the next cell
cycle, whereas CDK2low cells require MEK activity to transition
out of the CDK2low state back to the cycling state (Figure 3C).
We then examined two additional cell types, primary human
foreskin fibroblasts (Hs68 cells) and a previously used model
for cell-cycle progression, murine Swiss 3T3 cells. Both cell
types displayed a bifurcation in CDK2 activity at mitotic exit,
similar to MCF10A cells. However, the fraction of CDK2low cells
was slightly larger in Hs68 cells (39%, Figure 3D) compared to
MCF10A cells, and much larger in Swiss 3T3 cells (77%, Fig-
ure 3E). For both Hs68 and Swiss 3T3 fibroblasts, cells also
tended to persist in the CDK2low state for longer durations than
MCF10A cells. This argues that the bifurcation at mitotic exit is
likely a general cell-cycle mechanism but that the fraction of cells
bifurcating into each state as well as the time cells spend in the
CDK2low state vary between cell types, growth factor concentra-
tions, and other experimental conditions (Figure S4).
To determine which cyclin partner of CDK2 was responsible
for the immediate build-up of CDK2 activity after mitosis, we
treated cycling cells with siRNA against cyclin E and cyclin A.
Cells treated with siRNA targeting cyclin E during the previous
cell cycle failed to build up CDK2 activity after mitosis and
behaved similarly to CDK2low cells (Figure 3F). As in cells
emerging from quiescence, cyclin A was required to raise
CDK2 activity above a Cyt/Nuc DHB-Ven ratio of one. Thus,
the initial rise in DHB-Ven signal requires cyclin E/CDK2 activity,
after which cyclin A/CDK2 takes over in S phase. UsingCer-Cdt1
to mark the start of S phase, we found that neither the CDK2inc
nor the reactivating CDK2low MCF10A cells entered into S phase
until DHB-Ven rose above a Cyt/Nuc ratio of approximately one
(Figures 3G and 3H). This was the same ratio that we observed
(Figure 2D) for cells emerging from serum starvation. When we
used EdU incorporation to monitor DNA replication in individual
cells, we found that S phase was restricted to a window of CDK2
activity that corresponds to a DHB-Ven Cyt/Nuc ratio of 0.9–1.1
(Figure 3I). Together with the results from Figure 2, these exper-





Figure 2. A Variable Delay in CDK2 Activation in Cells Emerging from Mitogen Starvation
(A) Literature-based schematic of the signaling pathway involved in emergence frommitogen starvation. Mitogens promote upregulation of cyclin D, which binds
to CDK4/6 to initiate phosphorylation of Rb. This initiates the release of E2F from its Rb-bound state, freeing it to upregulate cyclin E, cyclin A, CDK2, and other
genes needed for S phase. p21 inhibits CDK2.
(B) Tracking of three cells, two of which divide, over 25 frames (5 hr).
(C) Left: images of MCF10A cells emerging from mitogen starvation. An arrow marks the cell tracked in the plot on the right. Top: H2B-Cherry; middle, Cerulean-
Cdt1; bottom, DHB-Venus. Right, traces of the cell marked with the arrow in the images. Cer-Cdt1 is degraded at the start of S phase (vertical dashed line)
(Sakaue-Sawano et al., 2008); at this time, the Cyt/Nuc ratio of DHB-Ven is about one.
(D) Traces of CDK2 activity in individual cells emerging from 45 hr of mitogen starvation that do (blue) or do not (black) enter S phase during the imaging period.
Because there were always a few cells that were not properly starved, only cells with DHB-Ven Cyt/Nuc < 0.8 at t = 0 are included in the plot. A red dot marks the
start of S phase (induction of Cer-Cdt1 degradation) for each cell.
(E) Traces of CDK2 activity in individual cells emerging from mitogen starvation. Cells were treated for 6 hr with a nontargeting siRNA (blue) or with a pool of four
siRNAs against cyclin A2 (green). Cells were then starved for 45 hr then restimulated with full growth media and subjected to time-lapse imaging. Only cells with
DHB-Ven Cyt/Nuc < 0.8 at t = 0 are included in the plot.
All data are from MCF10A cells. See also Figure S2 and Movie S1.









Figure 3. Bifurcation in CDK2 Activity upon Exit from Mitosis
(A) Single-cell traces of CDK2 activity in proliferating cells. CDK2 activity drops rapidly at mitosis (M) and either immediately builds up again or remains low for a
variable amount of time, reminiscent of a G0-like state.
(B–E) Single-cell traces of CDK2 activity aligned computationally to the time of anaphase for MCF10A (B and C), Hs68 primary human fibroblasts (D), or murine
Swiss 3T3 fibroblasts (E). Traces were colored red if, 2 hr after anaphase the Cyt/Nuc ratio of DHB-Ven fell below 0.55 (MCF10A) or 0.5 (Hs68); otherwise traces
were colored blue. The dashed line marks the cutoff used for the red/blue color scheme. Due to higher noise in Swiss 3T3 traces, we used an expanded rule for
these cells in which traces were colored red if the Cyt/Nuc ratio of DHB-Ven fell below 0.5 at 2 hr after anaphase or below 0.6 at 6 hr after anaphase; otherwise
traces were colored blue. This red/blue color scheme is used in all subsequent figures. In (C), MCF10A cells were preimaged for 8 hr, and then treatedwith 100 nM
(legend continued on next page)
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(Figure 3J): (1) CDK2inc cells begin to build up CDK2 activity if
they are born with CDK2 activity above a minimal trigger
threshold, (2) cells start DNA replication a few hours later after
they cross an intermediate CDK2 activity threshold, and (3) cells
finish G2 with an even higher level of CDK2 activity.
Variability in cell-cycle duration has long been attributed to
variability in the duration of G1 (Prescott, 1968), but the source
of this variability was not well understood. We found that the
distribution of the time MCF10A cells spend between M and S
was long-tailed, with some cells having very long M-to-S inter-
vals (Figures 3K and 3L). The relationship between the duration
of the M-to-S interval and the intermitotic time had a slope
close to one (Figure 3K), arguing that an increase of 1 hr in the
M-to-S interval results in an increase of 1 hr in total cell-cycle
time. Moreover, the time that individual cells spent between M
and S explained 70% of the variance in the overall cell-cycle
duration. Cells that pass through the CDK2low state had long
and variable M-to-S intervals, whereas the time spent between
M and S for CDK2inc cells was short (5–7 hr) and relatively
invariant (Figure 4L; coefficient of variation = 0.26 for CDK2inc
cells versus coefficient of variation = 0.42 for all cells with a finite
M-to-S interval). Thus, the time cells spend between mitosis and
S phase can potentially be described as a G1 phase character-
ized by steadily increasing CDK2 activity, preceded in a fraction
of cells by a transient G0-like state of variable duration charac-
terized by low CDK2 activity.
Residual CDK2 Activity and Hyperphosphorylation of Rb
Immediately after Mitosis
We next investigated whether CDK2inc cells exit mitosis with re-
sidual CDK2 activity, as suggested by the intermediate Cyt/Nuc
ratio of DHB-Ven in Figures 3B–3E. Indeed, addition of CDK1/2
inhibitor to CDK2inc cells reduced the Cyt/Nuc ratio of DHB-
Ven to a level lower than that observed at mitotic exit and similar
to that of CDK2low cells (blue, Figures 4A and 4B), confirming
that CDK2inc cells exit mitosis with residual CDK2 activity. In
contrast, addition of CDK1/2 inhibitor to CDK2low cells did not
further reduce the Cyt/Nuc ratio, indicating that these cells
have the minimal measurable level of CDK2 activity (red, Figures
4A and 4B).
We then investigated why some cells exit mitosis with residual
CDK2 activity, whereas others do not. We first tested whether
local cell density plays a role, but found that the number of neigh-
boring cells was similar in CDK2inc and CDK2low cells under ourMEKi (PD032591). Only cells that had completed anaphase 1–3 hr prior to additio
period.
(F) Single-cell traces of CDK2 activity aligned computationally to the time of anaph
(green) or cyclin E1 and E2 (red). Cells were incubated with siRNAs for 6 hr, was
(G andH) Traces of CDK2 activity aligned computationally to the time of anaphase
red dots. Cells not yet in S phase at the end of the movie are marked with black
(I) Density scatter plot of CDK2 activity versus EdU incorporation (a marker for D
(J) CDK2 activity in single cells at the start of G0/G1 (1 hr after nuclear envelope re
phase (last frame before nuclear envelope breakdown).
(K) Scatter plot showing the total duration of the cell cycle (intermitotic time) as a
was scored using Cer-Cdt1; mitosis was scored using H2B-Chy. Fit was obtaine
(L) Histogram of time spent between mitosis and the start of S phase for individua
through the CDK2low state (red). CV, coefficient of variation.
All data are from MCF10A cells except (D) and (E). See also Figure S3 and Movieexperimental conditions in which cells remain subconfluent (Fig-
ure S4). We also noted that sister cells chose the same CDK2inc
or CDK2low fate 98% of the time, suggesting that they share
an event in their past that regulates which path a pair of sister
cells takes. To examine the process at a molecular level, we
compared the endogenous levels of key proteins in single
CDK2inc and CDK2low cells immediately after the bifurcation.
We established a method in which we fixed cells at the end of
a time-lapse imaging series, stained them with antibodies, and
used a custom jitter correction script to map each cell in the
immunofluorescence image back to the same cell recorded in
the CDK2 time-lapse analysis (Figure 4C, Movie S3, and
Extended Experimental Procedures). We used this method to
monitor a number of potential regulators of the bifurcation
including cMyc, cyclin D1, cyclin E, cyclin A2, p21, p27,
phospho-Rb, the stress marker phospho-p38, and the DNA
damage marker gH2AX. We found that only phospho-Rb and
p21 levels were clearly statistically different in CDK2inc and
CDK2low cells immediately after the bifurcation (Figures 4D–4H,
and S4).
Consistent with our finding that Rb is a highly sensitive CDK2
substrate that requires only minimal CDK2 activity to become
phosphorylated (Figure 1I), CDK2inc cells were born with hyper-
phosphorylated Rb. In contrast, most cells in the CDK2low state
showed low Rb phosphorylation (Figures 4E and 4F). These two
distinct sub-populations of phospho-Rb were already evident
within the first hour after anaphase (Figure S4). When we exam-
ined the relationship between DHB-Ven and phospho-Rb in
large numbers of proliferating cells, we found a strong, nonlinear
correlation: cells with hypophosphorylated Rb always had a very
low Cyt/Nuc DHB-Ven ratio, whereas cells with hyperphos-
phorylated Rb had intermediate to high Cyt/Nuc DHB-Ven ratios
(Figure 4I). Thus, 75% of MCF10A cells exit mitosis with resid-
ual CDK2 activity and hyperphosphorylated Rb.
The Bifurcation in CDK2 Activity Is Controlled by p21
Using our approach of time-lapse imaging followed by immuno-
fluorescence, we also observed a strong inverse relationship
between the presence of residual CDK2 activity and endoge-
nous levels of the CDK inhibitor p21 (Figures 4G and 4H). The
levels of p21 were elevated in cells born into the CDK2low state,
whereas p21 levels remained low in CDK2inc cells throughout the
cell cycle. Thus, variation in endogenous p21 levels is correlated
with, and perhaps responsible for, the decision made at then of MEKi are plotted. MEKi remained in the media for the rest of the imaging
ase for cells treated with nontargeting siRNA (blue), siRNAs targeting cyclin A2
hed, and immediately subjected to time-lapse imaging.
. The start of S phase (induction of Cer-Cdt1 degradation) is markedwith blue or
Xs.
NA synthesis).
formation), at the start of S phase (scored using Cer-Cdt1), or at the end of G2
function of the M-to-S interval in individual cells (n = 176). The start of S phase
d by linear regression; R represents the Pearson correlation coefficient.
l MCF10A cells (n = 250). Brackets mark CDK2inc cells (blue) or cells that pass
S2.
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bifurcation. When we plotted the DHB-Ven versus p21 signal in
single cells, we found that the two are mutually exclusive: cells
with high p21 always had low Cyt/Nuc DHB-Ven ratios, whereas
cells with low p21 had intermediate to high Cyt/Nuc DHB-Ven
ratios (Figure 4J). Because p21 is a direct upstream regulator
of CDK2 activity, we decided to investigate the role of p21 in
the regulation of the bifurcation.
If high levels of p21 were responsible for causing a cell to enter
the CDK2low state after mitosis, one would expect that cells
lacking p21 would be unable to enter the CDK2low state. We
therefore made use of p21/ MCF10A cells (Bachman et al.,
2004), transduced them with DHB-Ven, and performed time-
lapse imaging of asynchronous cells as in Figure 3B. Strikingly,
when we imaged parental and p21/ MCF10A cells in parallel,
we found that p21/ MCF10A very rarely entered the CDK2low
state (<2% CDK2low for p21/ cells versus 26% for parental
cells) (Figure 5A). The intermitotic times of CDK2inc cells were
similar in parental and p21/ MCF10A cells, arguing that the
reported faster population doubling rate of p21/ cells is pri-
marily due to absence of the CDK2low state.
We then rescued the phenotype of p21/MCF10A cells using
the dihydrofolate reductase (DHFR)-trimethoprim (TMP) protein
stabilization system (Iwamoto et al., 2010) to acutely increase
exogenous p21 protein. When the DHFR domain from E. coli is
fused to a protein of interest, the entire fusion protein is continu-
ously degraded by the proteasome. Addition of the small mole-
cule ligand TMP rapidly stabilizes the fusion protein (Figure 5B).
We transduced p21/MCF10A cells with an exogenous copy of
p21 tagged with DHFR and mCherry, thereby gaining temporal
control of the level of p21 in these cells. Under basal conditions
(no TMP), p21 was destabilized and nearly all cells entered the
CDK2inc state after mitosis, as expected (Figure 5C, top, and
S5). To test whether an increase in p21 protein at the end of
the previous cell cycle causes cells to enter the CDK2low state
after mitosis, we added TMP to asynchronous cultures and
selected for analysis only those cells that were in G2 or M
when TMP was added. Remarkably, we found that we were
able to control, in a dose-dependent manner, the fraction of
CDK2inc versus CDK2low cells simply by regulating the level of
p21. At an intermediate dose of TMP, resulting in intermediate
levels of p21, a fraction of cells entered the CDK2low state (Fig-
ure 5C,middle, red), while the remainder built up CDK2inc activityFigure 4. CDK2inc Cells Begin G1 with Residual CDK2 Activity, Hyperp
(A) CDK2 activity in cells treated with 10 mMCDK1/2 inhibitor after 22 hr of imaging
marked as D.
(B) Boxplot of D. D is close to zero for CDK2low cells indicating no residual CDK2
(C) Time-lapse imaging of CDK2 activity in asynchronous cells was followed by
image was precisely aligned to the time-lapse imaging movie using a custom jitter
cell to its phospho-Rb level at the end of the movie (right).
(D) Example traces of CDK2 activity for CDK2inc and CDK2low cells used in (E)–(H).
second mitosis.
(E and G) Time-lapse imaging of CDK2 activity in asynchronous cells was followed
described in (C). Phospho-Rb levels (E) or p21 levels (G) were then reconstructed
cells (red dots). Brackets mark the time window (2–3.5 hr after anaphase) used i
(F and H) Boxplots comparing phospho-Rb staining (F) or p21 staining (H) in CDK
sum test was used to obtain p values.
(I and J) Density scatter plot of Cyt/Nuc DHB-Ven versus pRb807/811 (I) or vers
All data are from MCF10A cells. See also Figure S4 and Movie S3.(Figure 5C, middle, blue; these were invariably the cells with
lower p21 levels). At the highest dose of TMP, resulting in high
levels of p21, 100% of cells entered the CDK2low state after
mitosis (Figure 5C, bottom). Together, our knockout and
inducible-rescue experiments demonstrate that, for our experi-
mental conditions, p21 is necessary and sufficient to trigger
entry into the CDK2low state at mitotic exit.
Location of the Restriction Point
Nearly every cell that initiated a buildup of CDK2 activity in early
G1 continued to increase CDK2 activity until the subsequent
mitosis (Figures 3B–3E). This suggests that the time of bifurca-
tion represents a cell-cycle commitment for CDK2inc cells and
that the quiescence-proliferation decision window in these cells
might occur at the end of the previous cell cycle (Figure 6A, right).
However, this idea conflicts with the classic model of the restric-
tion point in which cell-cycle commitment occurs in late G1 (Fig-
ure 6A, left). To directly test where the restriction point is
positioned in cycling cells, we preimaged asynchronous cultures
to obtain cell-cycle phase information, then removed mitogens
and followed the cellular response. Every MCF10A cell that initi-
ated a buildup in CDK2 activity continued on its trajectory and
completed mitosis even if mitogens were withdrawn at any
time within G1, S, or G2. Mitogen withdrawal did not significantly
alter the duration of the ongoing cell cycle but did promote entry
into the CDK2low state after the subsequent mitosis (Figures 6B–
6E). We obtained similar results in Hs68 and Swiss 3T3 cells
(Figure S6).
To determine the precise timing of these events in MCF10A
cells, we scaled up our analysis and used a heatmap represen-
tation to quantify the results (Figure 6C). It then became apparent
that if mitogens were removed more than 8 hr before mitosis,
cells would enter the CDK2low state after mitosis and become
quiescent. If mitogens were removed in a window 0–8 hr prior
to mitosis, cells showed a decreasing probability of entering
the proliferative state with a midpoint approximately 3 hr prior
to anaphase (Figure 6E). If mitogens were withdrawn after
mitosis, cells entered the CDK2inc state with the same probability
as control cells and completed one additional cell cycle before
becoming quiescent. We then considered that we may not
have removed all growth factors or that growth factor signaling
may have continued from internalized growth factor receptors.hosphorylated Rb, and Low p21
. The difference between CDK2 activity at mitotic exit and after drug addition is
activity at mitotic exit.
immunofluorescence staining for pRb807/811 (left). The immunofluorescence
correction algorithm. This enabled matching of the CDK2 activity trace of each
For clarity, cells were excluded if they emerged from the CDK2low state or had a
by fixation and immunofluorescence staining for pRb807/811 (E) or p21 (G) as
as a function of time since anaphase for CDK2inc cells (blue dots) and CDK2low
n the boxplots in (F) and (H).
2inc and CDK2low cells selected to be within 2 to 3.5 hr after anaphase. A rank-
us p21 (J) obtained by fixed-cell imaging in asynchronously cycling cells.




+ 5µM TMP + 5µM TMP
+ 0.05µM TMP
Figure 5. The Bifurcation in CDK2 Activity Is
Controlled by p21
(A) Single-cell traces of CDK2 activity in parental
MCF10A and p21/ MCF10A aligned to the time
of anaphase.
(B) Design of the DHFR-mCherry-p21 construct.
(C) p21/ MCF10A cells expressing DHFR-
mCherry-p21 were preimaged for 6 hr, and then
treated with DMSO or with 0.05 mM or 5 mM TMP.
Traces were aligned to the time of anaphase and
only cells that were treated with TMP 0–4 hr prior
to anaphase (gray shaded region) were selected
for plotting. Left column, DHFR-mCherry-p21 in-
tensity in single cells over time. Right column,
consequent CDK2 activity in the same single cells
over time. Traces were colored blue if a buildup of
CDK2 activity occurred after mitosis, otherwise
traces were colored red.
See also Figure S5.We therefore suppressed growth factor signaling by adding a
MEK inhibitor to cycling cells and obtained similar results (Fig-
ures 6D and 6E and Movie S4).378 Cell 155, 369–383, October 10, 2013 ª2013 Elsevier Inc.We then scaled up our mitogen with-
drawal experiments in cycling Swiss 3T3
cells to more directly compare our find-
ings to studies by Zetterberg (Zetterberg
and Larsson, 1985) who investigated the
restriction point in cycling Swiss 3T3 cells
using bright-field time-lapse microscopy.
In their experiments, serum withdrawal
within the first 4 hr after mitosis led to an
immediate lengthening of G1 within the
same cell cycle, in apparent conflict with
our findings. As in MCF10A, we found
that CDK2inc Swiss 3T3 cells (only 20%
of cells) were immune to serum with-
drawal at any time in G1, S, or G2, but
would enter into the CDK2low state after
completing the next mitosis (Figures 6F
and 6G). However, a majority (80%)
of Swiss 3T3 cells naturally enter the
CDK2low state after mitosis (Figure 3E)
and therefore remain sensitive to serum
withdrawal as long as they have low
CDK2 activity (Figures 6F–6G and S6).
Thus, Zetterberg and Larsson (1985)
likely described a restriction point
(serum-sensitivity window) in mid to late
G1 because they used a cell type in which
the dominant behavior is entry into the
CDK2low state after mitosis.
These results suggest that cells inte-
gratemitogenic inputs in G2/M of the pre-
vious cell cycle during a first restriction
window (R1), and then bifurcate into either
a CDK2inc or CDK2low cell fate after
completing mitosis. One consequenceof the location of R1 is that sister cells typically share the same
fate upon completion of mitosis. Once cells enter the CDK2inc
state, they are committed to completing the cell cycle whether
mitogenic stimuli and MEK activity are present or not. Cells in
the CDK2low state face another decision point that is mitogen
sensitive (R2) in which they can build up CDK2 activity and re-
enter the cell cycle. If mitogens are withdrawn orMEK is inhibited
while cells are in the CDK2low state, cells will persist in this state
(Figure 6H).
DISCUSSION
A Live-Cell Sensor for CDK2 Activity that Marks a
G0-Like State and Tracks Interphase Progression
The ability to monitor events at the molecular level in unper-
turbed single cells marks an improvement over previous
methods of studying the G0 and G1 phases of the cell cycle.
Although there may be many forms of quiescence (O’Farrell,
2011), a unifying feature of quiescence is a lack of progression
through the cell cycle, which is readily detectable with our
CDK2 sensor. It is tempting to use this new capability to monitor
CDK2 activity in single cells to revisit the nomenclature of G0 and
G1 phases of the cell cycle. For cells emerging from a starvation-
induced G0 state, the CDK2low state could be interpreted as a
continued G0 state that persists for at least 8 hr after mitogen
addition, and the initial activation of CDK2 could be interpreted
as the beginning of the G1 phase. We therefore propose that
the CDK2low state could serve as a marker for the currently
imprecisely defined G0 phase, and that the initiation of CDK2
activation could serve as a marker for the start of G1. Alterna-
tively, the CDK2low state could be described as early G1 and
entry into the CDK2inc state as late G1, but this nomenclature
does not distinguish if or when a switch from G0 to early G1
occurs, nor does it reflect the fact that a fraction of the CDK2low
cells remain permanently in this state. The stereotypical increase
in CDK2 activity throughout G1, S, and G2 demonstrates that
DHB-Ven also provides a long sought-after molecular timer for
progression through interphase. Finally, previous classifications
of committed versus uncommitted cells required a perturbation
(mitogen withdrawal) followed by observation of future events
(mitosis) in order to retrospectively determine whether a cell
had crossed the restriction point at the time of mitogen with-
drawal. In contrast, our CDK2 sensor allows one to determine
a cell’s commitment to the cell cycle without needing to perturb
it or monitor its future behavior.
Unification of Our Results and Previous Observations
There are several discrepancies between our results and previ-
ous publications. First, we were initially surprised to observe a
gradual increase in CDK2 activity beginning shortly after nuclear
envelope reformation, as it is commonly believed that CDK2
activity only increases at the end of G1 (Hochegger et al.,
2008; Massague´, 2004). Second, the presence of hyperphos-
phorylated Rb in newly born CDK2inc cells in our studies was
unexpected because previous studies found Rb to be fully de-
phosphorylated during mitosis and only fully rephosphorylated
in late G1 (Buchkovich et al., 1989; Chen et al., 1989; Ludlow
et al., 1993; Ludlow et al., 1990; Mihara et al., 1989; Weinberg,
1995). Third, we initially expected to see a boost in CDK2 activity
at the G1/S transition in cycling cells as CDK2 overcomes inhibi-
tion by p21 and promotes p21 degradation (Abbas and Dutta,2009). Instead, we observe a steady ramp of CDK2 activity in
CDK2inc cells that is unaffected by the rapid induction of ubiquitin
ligase activity at the G1/S transition. This is consistent with a
fourth unanticipated result, in which we find that p21 levels
remain uniformly low in CDK2inc cells, starting from birth.
Our use of single-cell analysis in cycling cells can explain the
discrepancies with past studies in which synchronization and
bulk analysis were used. The previously observed multihour
delay in the phosphorylation of Rb and the activation of CDK2
can be attributed to the use of synchronization via mitogen star-
vation, which sets cells far back into G0. Measurements of the
extent of Rb dephosphorylation in mitosis were previously per-
formed in cells synchronized by nocodazole, which triggers a
stress response and increases p21 (Lanni and Jacks, 1998;
Uetake and Sluder, 2010), and we show in our experiments
that increased p21 during G2 causes entry into the CDK2low
and hypophosphorylated Rb states in the next cell cycle. The
lack of a noticeable increase in CDK2 activity at the G1/S transi-
tion can be explained by the fact that CDK2inc cells start the cell
cycle with already low p21. Thus, we believe that our results
represent an internally consistent set of observations.
Identification of a Bifurcation in CDK2 activity at the End
of Mitosis That Is Controlled by p21
Our study shows that cycling cells cross a bifurcation point at the
end of mitosis where they either immediately build up CDK2
activity and start the next cell cycle or enter a transient G0 state
characterized by low CDK2 activity (Figure 7A). Independent of
whether cells enter the cell cycle directly from mitosis or out of
a G0-like state, we identified a requirement for a threshold level
of CDK2 activity for DNA replication to begin. This notion is
consistent with previous work in S. pombe demonstrating that
S phase is triggered at an intermediate threshold level of CDK
activity (Coudreuse and Nurse, 2010).
The fraction of cells that bifurcate into the CDK2inc or CDK2 low
state after mitosis varies among different cell types and is regu-
lated by the strength of mitogen stimulation. CDK2inc cells have
a relatively short and invariant G1 phase of approximately 5–7 hr
duration. In contrast, CDK2low cells spend variable amounts of
time in this transient G0-like state that lengthens the total cell-
cycle timeand explainsmost of the observed variability in intermi-
totic time. Thus, the fraction of cells that pass through a G0-like
state and the amount of time they remain in this state appear
to be critical determinants of the population doubling time.
Under optimal proliferation conditions, the path a cell takes in
the bifurcation is directly controlled by p21. We demonstrate the
central role of p21 by showing (1) that the CDK2inc versus
CDK2low decision closely correlates with the endogenous level
of p21 in single cells, (2) that p21-null MCF10A cells rarely enter
the CDK2low state, and (3) that rapid induction of p21 protein
immediately prior to mitosis causes cells to enter the CDK2low
state upon completion of mitosis. Together, these results show
that, for our experimental conditions, p21 is necessary and suf-
ficient to control the bifurcation in CDK2 activity at mitotic exit.
There are two potential benefits to the tunability of this system.
At a cell-intrinsic level, even healthy cycling cells need time to
deal with metabolic imbalances or errors arising from DNA repli-








(legend on next page)
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for cells to deal with these challenges. At a tissue level, the ability
to regulate the fraction of cells entering a proliferative or a quies-
cent state allows for control of tissue homeostasis.Evidence for Two Restriction Windows in the Cell Cycle
The restriction point was originally defined as a point in late G1
after which cells would continue through the cell cycle even if
mitogens were withdrawn (Pardee, 1974). It has also been pro-
posed that commitment to the next cell cycle is made at the
end of the preceding cycle (Chassot et al., 2008; Hitomi and Sta-
cey, 1999). Our study argues that these apparently contradictory
models can be explained by taking into account the two types of
cell behaviors that we have observed within the same cell popu-
lation. Our results argue that cells integratemitogenic and poten-
tially other inputs during a restriction window at the end of
the previous cell cycle (R1) to regulate the bifurcation into the
CDK2inc or CDK2low state upon completion of mitosis. Only the
cells in the CDK2low state experience a second restriction win-
dow (R2) in which mitogens are needed to re-enter the cell cycle
and build up CDK2 activity. Given the different fractions of
CDK2low cells we found in the cell types we tested, the relative
importance of R1 versus R2 will vary depending on the cell
type, strength of mitogen stimuli and other conditions. Although
the two restriction windows R1 and R2 cover different phases of
the cell cycle, they reflect an underlying principle that cells
require the continued presence of mitogens for several hours
before they commit to building up CDK2 activity (Figure 7B).
Finally, the relationship between CDK2 activity and cell-cycle
commitment that we describe here may be integral to other
cell fate decisions such as the senescence of somatic cells,
the differentiation of stem cells, or the progression of cancer
cells.EXPERIMENTAL PROCEDURES
Cell Lines
MCF10A humanmammary epithelial cells were obtained from the laboratory of
Dr. Joan Brugge and cultured as described previously in MCF10A full growth
media (Debnath et al., 2003). Hs68 primary human foreskin fibroblasts (#CRL-Figure 6. Mitogenic Stimuli during the Previous Cell Cycle Control CD
(A) The following experiments are aimed at determining whether cell-cycle comm
end of the previous cell cycle (right).
(B) Cells were preimaged in full growth media, washed three times, and then trans
builds up even when mitogens are removed as early as 25 min after anaphase (
normalized traces of Cer-Cdt1 used to determine the start of S phase. Mit, mitog
(C and F) Heatmap of CDK2 activity in MCF10A cells (C) or Swiss 3T3 cells (F)
represents the CDK2 activity trace of a single cell over time. After 8 hr of preimagin
line) or washed and put in starvation media (right, vertical black line).
(D) Same as (C), except instead of removing mitogens after 8 hr of preimaging, M
100 nM MEKi (PD032591) in full growth media.
(E) Probability of quiescence following M0, for the case of mitogen withdrawal (r
quiescent if, 6 hr after M0, the DHB-Ven Cyt/Nuc ratio was less than one. Error b
(G) For each Swiss 3T3 cell, the time between the last mitosis and the time serum
the subsequent cell cycle (intermitotic time). Points are red if CDK2 activity was no
was already building up when mitogens were removed.
(H) Schematic of key decision points in cell-cycle commitment based on our data
the previous cell cycle and choose between CDK2inc and CDK2low fates upon com
can re-enter the cell cycle by building up CDK2 activity.
All data are from MCF10A cells except (F) and (G). See also Figure S6 and Movie1635) and Swiss 3T3 murine fibroblasts (#CCL-92) were obtained from ATCC
and cultured in DMEM plus 10% FBS and penicillin/streptomycin. Hs68 cells
were used for experiments up to passage 16 after receipt of the cells.
Constructs
cDNAs for Histone 2B fused to mCherry or mCerulean, Cdt1 (aa30–120)
(Sakaue-Sawano et al., 2008) fused to mCerulean, and DHB (aa994–1087)
(Hahn et al., 2009) fused to mVenus were cloned into the CSII-EF lentiviral vec-
tor. Transduced cells were sorted on a Becton Dickinson Influx to obtain pure
populations expressing the desired fluorescent reporters. cDNAs for DHFR-
R12Y/G67S/Y100I (Iwamoto et al., 2010), mCherry, and human p21 were
cloned into the pCru5 MoMLV retroviral vector and selected with 1 mg/ml
puromycin for 3 days.
Immunofluorescence
Cells were fixed in 4% formaldehyde, washed twice with PBS, permeabilized
with 0.2% triton, and stained overnight at 4C with apRb807/811 (Cell
Signaling Technology #9308) or ap21 (BD #556430). Primary antibodies
were visualized using a secondary antibody conjugated to Alexa Fluor-647
and imaged with a far red filter. For Figure 3I, cells expressing DHB-Ven
were treated with 10 mM EdU for 15 min and fixed and processed according
to manufacturer’s instructions (Invitrogen # C10356).
Inhibitors
The inhibitors used in this study were: PD0325901 (MEK inhibitor), Gefitinib
(EGFR inhibitor), SB 203580 (p38 inhibitor), MK-2206 (Akt inhibitor), GDC-
0941 (PI3K inhibitor), VX-680 (Aurora kinase inhibitor), RO3306 (CDK1 inhibi-
tor), PD0332991 (CDK4/6 inhibitor), and EMD Biosciences #217714 (CDK1/2
inhibitor).
siRNA Transfection
MCF10A cells were transfected using Dharmafect 1 or 3 (Thermo Scientific)
according to the manufacturer’s instructions. The following siRNAs were
used: control siRNA (nontargeting #2), siGenome pooled set of four siRNAs
for cyclin A2, or siGenome pooled set of eight siRNAs for cyclin E1 and E2
(Dharmacon) at final concentrations of 20–25 nM.
In Vitro Kinase Assays
Kinase assays were performed by ProQinase GmbH. See Extended Experi-
mental Procedures.
Time-Lapse Microscopy and Image Processing
Images were taken on an ImagExpress5000A or on an IXMicro microscope
(Molecular Devices) and image processing was performed in MATLAB
(MathWorks). See Extended Experimental Procedures.K2 Activation and Commitment to the Next Cell Cycle
itment occurs in late G1 as posited by the restriction point model (left) or at the
ferred to media without mitogens after 8 hr (dashed line at t = 0). CDK2 activity
leftmost cell). Top, single-cell traces of CDK2 activity. Bottom, corresponding
ens.
sorted computationally by the time of mitosis (M0). Each row in the heatmap
g, cells were washed and put back in full growthmedia (mock, left, vertical black
CF10A cells were treated with DMSO (left, vertical black line), or treated with
ed), addition of 100 nM MEKi (green), or control (blue). A cell was considered
ars are standard deviation from duplicate experiments.
was removed was recorded (cell age at serum removal), as well as the length of
t yet building up when mitogens were removed; points are blue if CDK2 activity
. Cells integrate mitogenic stimuli during a restriction window (R1) at the end of
pletion of mitosis. CDK2low cells face a second decision point (R2) in which they
S4.
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Figure 7. Model for Cell-Cycle Commitment and Transitions
between G0 and G1
(A) Cells choose between CDK2inc and CDK2low fates during a restriction
window (R1) at the end of the previous cell cycle. Suppression of p21 protein
during this period sends cells into the CDK2inc state upon completion of
mitosis. These cells are born into G1, committed to the cell cycle, with low p21,
residual CDK2 activity, hyperphosphorylated Rb, and enter S phase in 5–7 hr.
Elevation of p21 protein at the end of the previous cycle sends cells into the
CDK2low state upon completion of mitosis. These cells are born into a transient
or prolonged G0-like state with high p21, no residual CDK2 activity, and
hypophosphorylated Rb. These cells remain sensitive to mitogen withdrawal
and are not committed to the cell cycle until they pass a second restriction
window (R2) prior to the buildup of CDK2 activity.
(B) Upon exit from mitosis, cells execute a quiescence-proliferation decision
by choosing between a CDK2low, G0-like state (red), and a CDK2inc, G1 state
(blue).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, one table, and four movies and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2013.08.062.
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